



MINICORSO 13

Sindrome adrenogenitale: diagnosi e gestione

Giovedì 7 Novembre 2013 ore 18.00 – 20.00 (ripetizione Venerdì 8 ore 11-13)




Bari,
7-10 novembre 2013

Classificazione ed Epidemiologia degli Iposurrenalismi

Corrado Betterle

(Dichiaro di non avere conflitto di Interessi)

U.O.C di Endocrinologia,
Cattedra di Immunologia Clinica
DIPARTIMENTO DI MEDICINA (DIMED)
UNIVERSITA' DEGLI STUDI DI PADOVA






1563

Bartolomeo Eustachio

Anatomico a Padova

in the Opuscola Anatomica (Venice 1563
described the existence of the adrenals as “de
glandulis quae renibus incumbent”



1855


Thomas Addison

Guy's Hospital di Londra,
descrive una malattia che colpisce

i surreni

e che porta a morte i pazienti
con una serie di disturbi:

**estrema stanchezza
e colorito bruno della cute.**



Thomas Addison

1856 Trousseau


l'insufficienza surrenalica fu
chiamata **“malattia di Addison”**

descrisse 11 pazienti in cui l'autopsia
rilevò a livello del surrene:

- 6 casi tubercolosi
- 3 casi tumori
- 1 caso emorragia
- 1 caso atrofia idiopatica

Questo probabilmente è la prima
descrizione di una forma autoimmune.

Three types of adrenocortical insufficiencies





Prevalence of Addison's disease in the World

(x million of inhabitants)



Bari,
7-10 novembre 2013



40	Cases in England (1968)
60	Cases in Denmark (1974)
93	Cases in England (1997)
110	Cases in England (1994)
117	Cases in Italy (2002)
144	Cases in Norway (2007)

In the years 1968-2004 the frequency of AD in Europe increased from 40-144 cases

4	cases in New Zealand
5	cases in Japan
50	cases in U.S.A.

- TUBERCULOSIS
- AUTOIMMUNITY
- OTHERS

In the past

60-80%

10-20%

5%

In recent years

10-15%

75-80%


5%


CLINICAL STUDY

European Journal of Endocrinology (2013) 169 773–784

Addison's disease: a survey on 633 patients in Padova

Corrado Betterle, Riccardo Scarpa, Silvia Garelli, Luca Morlin, Francesca Lazzarotto, Fabio Presotto¹, Graziella Coco[†], Stefano Masiero, Anna Parolo, Maria Paola Albergoni², Roberta Favero², Susi Barollo, Monica Salvà, Daniela Basso³, Shu Chen⁴, Bernard Rees Smith⁴, Jadwiga Furmaniak⁴ and Franco Mantero





In **Europe** the prevalence is: **90-144 cases/million**
(Inhabitants 731 Millions)

70-100.000 patients with Addison's Disease

Incidence: 4-6 new cases/million /year

3655 new cases/year = 10 new cases/day

In **Italy** the prevalence is: **117 cases/million**
(Inhabitants 60 Millions)


7.000 patients with Addison's disease

300 new cases/year = about 1 new case/day



Addison's disease: a survey on 633 patients in Padova

Corrado Betterle, Riccardo Scarpa, Silvia Garelli, Luca Morlin, Francesca Lazzarotto, Fabio Presotto¹, Graziella Coco[†], Stefano Masiero, Anna Parolo, Maria Paola Albergoni², Roberta Favero², Susi Barollo, Monica Salvà, Daniela Basso³, Shu Chen⁴, Bernard Rees Smith⁴, Jadwiga Furmaniak⁴ and Franco Mantero





Age at onset of Different aethiological Forms of Addison's disease



Bari,
7-10 novembre 2013

CLINICAL STUDY

European Journal of Endocrinology (2013) 169 773–784

Addison's disease: a survey on 633 patients in Padova

Corrado Betterle, Riccardo Scarpa, Silvia Garelli, Luca Morlin, Francesca Lazzarotto, Fabio Presotto¹, Graziella Coco[†], Stefano Masiero, Anna Parolo, Maria Paola Albergoni², Roberta Favero², Susi Barollo, Monica Salvà, Daniela Basso³, Shu Chen⁴, Bernard Rees Smith⁴, Jadwiga Furmaniak⁴ and Franco Mantero

APS1 ———
Non -APS1 ———
TBC-AD ———




Figure 2 Age at the onset of AD in patients with APS1, other forms of autoimmune AD (APS2, APS4, and isolated A-AD) and with tuberculosis disease (TBC-AD).



GENETIC FORMS IN PADUA SURVEY



Bari,
7-10 novembre 2013

CLINICAL STUDY

European Journal of Endocrinology (2013) 169 773–784

Addison's disease: a survey on 633 patients in Padova

Corrado Betterle, Riccardo Scarpa, Silvia Garelli, Luca Morlin, Francesca Lazzarotto, Fabio Presotto¹, Graziella Coco[†], Stefano Masiero, Anna Parolo, Maria Paola Albergoni², Roberta Favero², Susi Barollo, Monica Salvà, Daniela Basso³, Shu Chen⁴, Bernard Rees Smith⁴, Jadwiga Furmaniak⁴ and Franco Mantero

Genetic Forms 29/633 (4,6%)

Patients with genetic forms of AD

Twenty-four of 29 (all males) had adrenoleukodystrophy with a mean age at onset of 18 years (range 1–63), two had 21-hydroxylase deficiency, one had X-linked congenital adrenal hypoplasia with mutation of *DAX1* (*NROB1*) (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1), one had POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein skin abnormalities), and one had ACTH receptor mutation. ACA and 21-OH Abs were negative in 22 patients tested.

29 cases Adrenoleukodystrophy
2 cases 21-OH deficiency
1 case X linked
1 case POEMS
1 case ACTH receptor mutation

Primary Adrenal Insufficiency in Children: Twenty Years Experience at the Sainte-Justine

Rebecca Perry, Oufae Kecha, Jean Paquette, Celine Huot, Guy Van Vliet, and Cheri Deal

TABLE 1. Etiologies of PAI

Etiology	Females (n = 55)	Males (n = 48)	% of total (n = 103)	Age at diagnosis of PAI
21OH CAH				
Classic	30	29	57.3	
SW form	27	26	51.5	16 (1–2281) d ^a
SV form	3	3	5.8	5.8 (3.7–7) yr
Nonclassic	11	2	12.6	7.4 (5–10.3) yr
3- β -hydroxysteroid dehydrogenase deficiency CAH	1	1	1.9	17.5 (14–21) d
Autoimmune				
APECED	3	2	4.9	10.7 (5.4–13.6) yr
Non-APECED	5	3	7.8	14.6 (7.8–16.3) yr
Adrenoleukodystrophy	0	4	3.9	10.5 (4.3–14.3) yr
Syndromes				
Wolman disease	1	2	2.9	26 (25–49) d ^b
Triple A	0	1	1.0	10.3 yr
Zellweger disease	0	1	1.0	8.2 yr
X-linked AHC	0	1	1.0	4.6 yr
Unexplained isolated glucocorticoid deficiency	2	1	2.9	42 (6–122) d
Unexplained glucocorticoid and mineralocorticoid deficiencies	2	1	2.9	2.3 (1.2–4.3) yr

72%

12,7%

10%

^a If the boy with a late diagnosis made after identification of his virilized infant sister is excluded, the median is unchanged, but the range becomes 1–1125 d.

^b Age at presentation, not diagnosis (which was made postmortem; see *Results*).



PRIMARY ADRENOCORTICAL INSUFFICIENCY in Adult Population



Bari,
7-10 novembre 2013

	AETHIOLOGY	PREVALENCE
AUTOIMMUNE	Unknown	75-80%
TUBERCULOSIS	Mycobacterium TBC	10-12%
Other infections	Histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, North America blastomycosis, cryptococcosis, syphilis, HIV, CMV	1%
Cancer or Metastatic disease	Adenocarcinoma, lymphomas, plasmocytomas, metastasis of ovary, colon, kidney, melanoma, breast cancer	1-2%
Infiltrative disorders	Amyloidosis, haemochromatosis, histiocytosis	1%
Congenital and Genetics	agenesia, adrenoleukodystrophy, enzymatic defects, ACTH-receptor mutations, rare diseases	4-5%
Vascular	Thrombosis, haemorrhage, drugs, traumas	1%
Drugs	ketoconazole, mitotane, metopyrone, aminoglutethimide, trilostane, etomidate, rifampin, cyproterone acetate, fenitoin sodium, barbiturate	1%
Surgery	for Cushing sindrome, for cancer	1%

The pathway of adrenal cortex hormones

MINERALOCORTICOIDS

GLUCOCORTICOIDS

ANDROGENS

Cholesterol

Side chain cleavage

17 α -hydroxylase

17-20 lyase

Pregnenolone \rightarrow 17-OH Pregnenolone \rightarrow DHEA

3 β -OHDS

Progesterone \rightarrow 17-OH Progesterone \rightarrow Androstenedione

21-hydroxylase

11-Deoxycorticosterone 11-Deoxycortisol

Testosterone

11 β -hydroxylase

Corticosterone


Cortisol

Aldosterone

Zona glomerulosa

Zona fasciculata

Zona reticularis



CLINICAL MANIFESTATIONS OF ADDISON'S DISEASE

LABORATORY DIAGNOSIS OF ADDISON'S DISEASE

Symptoms Incidence %

Weakness and fatigue	100
Anorexia	100
Nausea, vomiting and diarrhea	50
Salt craving	20
Muscle, joint and abdominal pain	10
Postural dizziness	10
Depression, psychosis	10

Signs Incidence %

Weight loss (dehydration, vomiting, anorexia)	100
Orthostatic hypotension	90
Hyperpigmentation (skin, mucosae)	90
Decreased of axillary and pubic hairs	20

Natremia:	<i>low</i> (<135mMol/L)
Potasseemia:	<i>increased</i> (>4,5mMol/L)
Chloremia	<i>low</i> (<100 mMol/L)
Plasm. Osmolarity	<i>low</i>
AST/ALT	<i>increased</i>
Calcemia:	<i>increased</i>
Glicaemia:	<i>low</i>

eosinophilia
lymphocytosis
anemia

Cortisol:	<i>low</i>
ACTH:	<i>increased</i>
Aldosterone:	<i>low</i>
PRA:	<i>increased</i>
DEHAS:	<i>low</i>
TSH:	<i>increased</i>

CLINICAL MANIFESTATIONS OF ADDISON'S DISEASE







Addison's disease: a survey on 633 patients in Padova

Corrado Betterle, Riccardo Scarpa, Silvia Garelli, Luca Morlin, Francesca Lazzarotto, Fabio Presotto¹, Graziella Coco⁴, Stefano Masiero, Anna Parolo, Maria Paola Albergoni², Roberta Favero², Susi Barollo, Monica Salvà, Daniela Basso³, Shu Chen⁴, Bernard Rees Smith⁴, Jadwiga Furmaniak⁴ and Franco Mantero



Bari,
7-10 novembre 2013



Adrenal cortex antibodies (ACA) and 21-OH Abs in A-AD

APS-1 (11%)

APS-2 (51%)

APS-4 (7%)

Isolato (9%)



Morbo di Addison
+
Candidiasi Cronica
e/o
Ipoparatiroidismo

Bambini/Adulti 2/1
Età media 14 anni
F/M=1
Mutazioni GENE AIRE



Morbo di Addison
+
Malattie tiroidee
e/o
Diabete Mellito Tipo 1

Adulti/Bambini 16/1
Età media 35 anni
F/M=2/1
HLA-DR3 and/or DR4



Morbo di Addison
+
Altre malattie
autoimmuni (vitiligo,
alopecia, gastrite,
celiachia)

Adulti/bambini 5/1
Età media 35 anni
F/M=1
HLA-DR3 and/or DR4



Morbo di Addison
Senza altre malattie
autoimmuni

Adulti/Bambini 4/1
Età media 35 anni
F/M=0.6
HLA-DR3 and/or DR4





TUBERCULOSIS ADDISON'S DISEASE

57/633 cases (9%)


Pathology, Imaging and Laboratory



Bari,
7-10 novembre 2013




F/M 4/1
mean age 55



🏠 Adrenals Imaging:
-87% revealed adrenal masses with or without calcifications
-13% showed normal adrenal glands.


ADDISON'S DISEASE and Adrenoleukodystrophy

24/633 cases (3,9%)



ACA

Imaging



- 🏠 All patients were **males**
- 🏠 age at onset of AD **18 years**
- 🏠 VLCFA= **were increased**
- 🏠 Adrenal imaging= were normal
- 🏠 Brain imaging = **symmetrical demyelination**

In 5 patients the AD was the first manifestation



Etiological flowchart of Addison's disease in adults



Bari,
7-10 novembre 2013



ACTH ↑ CORTISOL ↓
Primary

ACA and/or 21-OH Abs

75%

25%

Positive

Negative

Autoimmune

Adrenal imaging

Adrenal imaging
Normal/atrophic
(not necessary)

Normal adrenal glands

Small hyperdense glands

Adrenal mass with or without calcifications

Atrophic or hyperplastic glands

Infarction or hemorrhage

Evaluation for other autoimmune diseases
(clinical and/or serological)

VLCFA
Negative Positive

Adrenal biopsy?

ACTH-test

ANA and/or APA

ACTH-R gene, SF-1, DAX-1, mitochondrial DNA deletions, enzyme defects

Positive Negative

SLE, APAS

Coagulation disorders, traumas, anti-coagulant therapy

Positive Negative
Genetic forms Idiopathic

Candidiasis and/or Hypoparathyroidism

TAD and/or Type 1DM

Presence of other autoimmune diseases

Absence of autoimmune diseases

Adrenoleukodystrophy

Hemochromatosis

TBC

Neoplastic disease

Amyloidosis, Sarcoidosis, Histiocytosis, Fungal or viral Diseases

APS 1

APS 2

APS 4

Isolated

Neurologic signs

Hemochromatosis

TBC in other organs

Neoplasia in other organs

Localization in other organs

AIRE GENE Mutations

HLA-DR

Chr. Xq28 mutations

HLA-DR

APAS = Anti-phospholipid syndrome; VLCFA = Very long chain fatty acids;
ACA = Adrenal-cortex autoantibodies; 21-OH Abs = 21-Hydroxylase autoantibodies
ANA = Anti-nuclear antibodies; APS = Autoimmune Polyendocrine Syndrome

Primary Adrenal Insufficiency in Children: Twenty Years Experience at the Sainte-Justine

Rebecca Perry, Oufae Kecha, Jean Paquette, Celine Huot, Guy Van Vliet, and Cheri Deal

